Investment: “PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava each raise €1.3 million”
Six bioscience and deep-tech startups developing cancer therapies, surgical imaging tools, treatments for inflammatory diseases, biological pest-control solutions, vaccine-based immunotherapies and sustainable biofuels — PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava — have each been awarded an additional convertible loan of €1.3 million by Copenhagen-based BioInnovation Institute, bringing the total capital each has received from the institute to €1.8 million.
Each of the six companies had previously secured €500,000 from BII. In February 2026 the institute also secured €25 million in Novo Nordisk Foundation funding to launch ‘Upscalator’, an initiative to support early-stage startups with facilities, services and expertise.
PanTarg, a University of Copenhagen and Rigshospitalet spin-out, is developing an antibody-based cancer therapy that combines two targeted attacks in one treatment aimed at aggressive cancers including pancreatic cancer. 3Sonic, spun out of Rigshospitalet and the Technical University of Denmark (DTU), is building a 3D ultrasound and AI imaging tool to help surgeons assess cancer tissue in real time during operations. Inia Biosciences, which grew out of innovation hubs in Boston and Oxford, is working on new treatments for inflammatory diseases, starting with psoriasis. Yngvi Bio, a University of Copenhagen spin-out, is developing biological pest-control solutions aimed at protecting crops while limiting harm to biodiversity and human health. Proxi Biotech, a spin-out from Statens Serum Institut, is developing a vaccine-based immunotherapy to treat recurrent bacterial infections, with a lead candidate targeting recurrent Clostridium difficile and intended as an alternative to treatments such as faecal microbiota transplantation. Sagava, a DTU spin-out, is converting waste into sustainable biofuels and energy to help decarbonise the maritime sector.
The fresh funding is intended to help the companies mature their technologies, strengthen their businesses and take further steps toward commercial application. Alongside the capital, the companies retain access to BII’s innovation platform in Copenhagen, including laboratory facilities, a network of investors, advisors and strategic partners, and support in business development and commercialisation, all aimed at positioning them to attract further external investment and move closer to market.
“The six companies have demonstrated strong potential and have already taken important steps from promising research to developing solutions that can make a real difference. With continued funding, they have the opportunity to accelerate their development and focus even more on their path towards the market,” said Trine Bartholdy, Chief Business Officer at BII.
